cytochrome P450 family 1 subfamily A member 1Genealiases: AHH · CP11 · CYP1 · CYPIA1 · P1-450 · P450-C
Q-omics provides the consensus-scored CYP1A1 profile across patient tissues and cancer cell-line models. CYP1A1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP1A1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CYP1A1 RNA expression shows 10,156 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where CYP1A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP1A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP1A1 survival associations across molecular data types. CYP1A1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP1A1 RNA expression–survival associations across cancer types. High CYP1A1 expression shows unfavorable associations in KIRC, ACC, UVM and UCS, but favorable associations in LGG and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP1A1 RNA expression.
This table summarizes CYP1A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CYP1A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP1A1 shows lower tumor expression in KIRC, LUAD, KIRP, BRCA, CHOL and LIHC. The KIRC box plot shows higher CYP1A1 RNA expression in normal versus tumor tissue (log2 FC = −1.240, t-test p < 0.001).
This table shows molecular features associated with CYP1A1 in patient tissues and cancer cell lines. In patient samples, CYP1A1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP1A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
